Готові списки джерел за темами / Molecular factor of recurrence

Зміст

Статті в журналах
Дисертації
Книги
Частини книг
Тези доповідей конференцій
Звіти організацій

Добірка наукової літератури з теми "Molecular factor of recurrence"

Автор: Grafiati

Опубліковано: 11 березня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Molecular factor of recurrence".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Molecular factor of recurrence"

Nomani, Homa, Sara Saei, Thomas P. Johnston, Amirhossein Sahebkar, and Amir Hooshang Mohammadpour. "The Efficacy of Anti-inflammatory Agents in the Prevention of Atrial Fibrillation Recurrences." Current Medicinal Chemistry 28, no. 1 (December 29, 2020): 137–51. http://dx.doi.org/10.2174/1389450121666200302095103.

Повний текст джерела

Анотація:

: Several studies have indicated an association between inflammation and the recurrence of Atrial Fibrillation (AF), especially after ablation, which is a therapeutic option leading to local inflammation. On the other hand, each AF can lead to another AF, as a general rule. Thus, preventing recurrences of AF is extremely important for patient outcomes. In this paper, we attempted to review the effect of medicinal agents with anti-inflammatory properties on the prevention of AF recurrence. There are several randomized controlled trials (RCTs) and meta-analyses on the prevention of AF recurrence using agents with anti-inflammatory properties, which include steroids, colchicine, statins, and n-3 fatty acids (n-3 FA). Clinical trials evaluating the efficacy of anti-inflammatory drugs in preventing the recurrence of AF led to inconsistent results for corticosteroids, statins and n-3 FAs. These results may be related to the fact that inflammation is not the only factor responsible for triggering recurrences of AF. For example, the presence of structural, mechanical and electrical remodeling could potentially be the most important factors that trigger recurrences of AF but these factors have not been addressed in most of the reported studies. Therefore, future clinical trials are needed to compare the efficacy of anti-inflammatory drugs in AF patients with, or without other factors. For colchicine, a potent anti-inflammatory drug, there are limited studies. However, all the studies investigating colchicine in the context of AF were consistent and promising, especially when colchicine was used on a short-term basis following ablation in patients with paroxysmal AF. Therefore, colchicine could be a promising candidate for further clinical studies involving recurrent AF.

Стилі APA, Harvard, Vancouver, ISO та ін.

Young, Guy, Fauke Friedrichs, Neil Goldenberg, Gili Kenet, Marilyn Manco-Johnson, Christine During, and Ulrike Nowak-Gottl. "Impact of the Factor II G20210A Variant and the Factor V G1691A on Recurrent Venous Thromboembolism in Children: An International Multicentre Cohort Study." Blood 110, no. 11 (November 16, 2007): 1641. http://dx.doi.org/10.1182/blood.v110.11.1641.1641.

Повний текст джерела

Анотація:

Abstract The recurrence rate of thrombosis in children following a first thrombotic event ranges from 3% in neonates to 8% in older children. The relative importance of the factor II and factor FV mutations is unknown. We present a multicentre cohort study to assess the rate of symptomatic VTE recurrence per 1000 person-years in children heterozgous for the FII and FV mutations following a first VTE. Data were pooled to increase power for the secondary aims, e.g. time to recurrence, and predictors of recurrence. Between January 1994 and December 2006, 251 consecutively enrolled VTE patients aged newborn to ≤18 years (median 5.2 years: male n=141) carrying the FII (n=61) or FV mutation (n=190) were followed for a median of 58 (max 156) months. 128 of 251 VTE patients (51%) had at least one underlying medical condition at VTE onset, and 15 were heterozygous for both mutations. Children received acute anticoagulation (AC) with unfractionated heparin or low-molecular weight heparin, followed by AC with LMWH or warfarin for a three to 6 month period in 70% of cases. Of the 251 patients enrolled, 24 (9.5%: recurrence rate of 19.3 per 1000 person-years, 95% confidence interval (CI): 12.9–28.8) had recurrent VTE at a median (min-max) of 3.5 (0.1–120) months. Not including combined defects, the recurrence rate per 1000 person-years was 41.4 (95%CI: 22.3–77) for patients with the FII mutation, and 14 (95%CI: 8.3–23.6) for carriers of the FV mutation. Median (min-max) age at recurrence was 13.4 (0.1–17) years, 12 of 24 patients were male (50%), and in 21 of 24 children (87.5%) recurrence occurred after withdrawal of AC. When comparing FII with FV subjects, Cox regression analysis showed that the factor II mutation (HR/95%CI: 2.5/1.1–5.9; p=0.031) was associated more frequently with a second VTE. In addition, older age (> 2 years) at first VTE onset (HR/95%CI: 1.1/1.01–1.14; p=0.025) independently influences the second VTE event [3.5 years (non-recurrence) vs. 12.7 years (recurrence); p< 0.0001]. Among patients suffering from recurrent VTE, 58% occurred within the first six months following VTE onset. Time to recurrence (FII vs. FII and age at onset >/< 2 ears) is shown in the Kaplan Meier analyses. The overall VTE recurrence rate of 9.5% is within the range recently reported in children. However, when comparing FII and FV carriers, the factor II G20210A variant is more often associated with a recurrent VTE. In addition, independently from the underlying gene mutation age > 2 years at first VTE increase the risk of a second symptomatic venous thrombosis. Figure Figure

Стилі APA, Harvard, Vancouver, ISO та ін.

Munguti, Cecilia, Miriam Claire Mutebi, Mukuhi Ng'ang'a, and Ronald Wasike. "Breast cancer recurrence rate in patients treated for early breast cancer." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e12508-e12508. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e12508.

Повний текст джерела

Анотація:

e12508 Background: Recurrence rates for early breast cancer vary in different studies from 7% to 18%. Recurrent breast cancer is associated with poorer outcome and higher mortality rates. The recurrence rate in the Kenyan population remains unknown despite high prevalence of known risk factors. Methods: Single institution retrospective study of all women (18 -75 years) treated for early breast cancer at a single center private tertiary unit from 2009 to 2017. Results: 239 patient records were reviewed. The mean age at diagnosis was 51 (SD13.1). 98% of women presented with a palpable breast lesion. The molecular sub-type’s prevalence was: ER/PR+ (76%), triple negative (12.1%), HER2+ (2.9%). The overall recurrence rate was 7.2%, 66% recurrences were loco-regional, while 27% were metastatic disease, with 61% of the recurrences being detected initially on clinical/ self-breast examination. 77% of the recurrences were in women with ER/PR+ molecular sub-types. Recurrences in women with DCIS (2/27) were invasive breast cancers. There were no identified risk factors on uni-variate and multivariate regression analysis which conferred a risk of breast cancer recurrence. Discussion: The mean age at diagnosis in this group is younger than the western average (65 - 75 years). Majority of the women presented with symptoms – a presentation that differs from that of countries with a national breast cancer screening program. The molecular distribution of breast cancers is comparable to western populations. Conclusions: Recurrence rate for early breast cancer in this series is 7.2%, which is comparable with documented western data, with majority of the recurrences being detected initially on clinical/self-breast examination.

Стилі APA, Harvard, Vancouver, ISO та ін.

Chen, Jie, Hui Qiu, Rui Chen, Jiani Huang, Liang Chen, Juncheng Wan, Qi Chen, and Longzhen Zhang. "Peritumor Edema Serves as an Independent Predictive Factor of Recurrence Patterns and Recurrence-Free Survival for High-Grade Glioma." Computational and Mathematical Methods in Medicine 2022 (July 27, 2022): 1–10. http://dx.doi.org/10.1155/2022/9547166.

Повний текст джерела

Анотація:

Objective. This study is aimed at analyzing the factors affecting the recurrence patterns and recurrence-free survival (RFS) of high-grade gliomas (HGG). Methods. Eligible patients admitted to the Affiliated Hospital of Xuzhou Medical University were selected. Subsequently, the effects of some clinical data including age, gender, WHO pathological grades, tumor site, tumor size, clinical treatments, and peritumoral edema (PTE) area and molecular markers (Ki-67, MGMT, IDH-1, and p53) on HGG patients’ recurrence patterns and RFS were analyzed. Results. A total number of 77 patients were enrolled into this study. After analyzing all the cases, it was determined that tumor size and tumor site had a significant influence on the recurrent patterns of HGG, and PTE was an independent predict factor of recurrence patterns. Specifically, when the PTE was mild (<1 cm), the recurrence pattern tended to be local; in contrast, HGG was more likely to progress to marginal recurrence and distant recurrence. Furthermore, age and PTE were significantly associated with RFS; the median RFS of the population with PTE < 1 cm (23.60 months) was obviously longer than the population with PTE ≥ 1 cm (5.00 months). Conclusions. PTE is an independent predictor of recurrence patterns and RFS for HGG. Therefore, preoperative identification of PTE in HGG patients is crucially important, which is helpful to accurately estimate the recurrence pattern and RFS.

Стилі APA, Harvard, Vancouver, ISO та ін.

Huybrechts, S., A. Chivet, A. Tauziede-Espariat, C. Rossoni, E. Indersie, P. Varlet, S. Puget, et al. "P14.99 Clinical and biologic features predictive of survival after relapse of childhood medulloblastoma." Neuro-Oncology 21, Supplement_3 (August 2019): iii91. http://dx.doi.org/10.1093/neuonc/noz126.334.

Повний текст джерела

Анотація:

Abstract BACKGROUND Salvage therapy for recurrent medulloblastoma (MB) is not standardized. Factors associated with survival after recurrence have not been reported. MATERIAL AND METHODS Medical records were reviewed for 155 consecutive patients with newly diagnosed MB between 2007 and 2017, treated at Gustave Roussy and Hospital Necker. The following variables were collected for all patients: age at diagnosis, stage, histology (central review according to WHO 2016 classification), molecular subgrouping (DNA methylation), first-line treatment modalities, time to relapse, pattern of recurrence and current status. RESULTS A disease recurrence was observed in 47 patients (30%) at a median time of 15 months (range, 1–88 months). The 1-year survival after recurrence was 44% (CI 95%,29.6 to 58.8). The pattern of recurrence was local in 9 patients, metastatic in 21 and combined local and metastatic in 17 patients. The time to first recurrence, less or more than 12 months from diagnosis, was a predictor of post-recurrence overall survival (p < 0.0001) after adjustment for age, treatment, MYC amplification and molecular subgroups. Twenty-seven patients (57%) experiencing recurrent or progressive disease more than 12 months after diagnosis, had an estimated 1-year survival after recurrence of 100% (CI 95%, 100.0 to 100.0) vs 30% (CI 95%, 12.2 to 50.1) with an earlier recurrence. Early relapse was more frequent in children younger than 5 years of age at diagnosis (75% vs 37%, p =0.009), anaplastic/large cell MB (30% vs 3.7%, p=0.046) and Group 3 tumours (76.5% vs 20.8%, p=0.003). Other factors influencing post-relapse survival were metastatic disease and treatment modalities at diagnosis. Multivariable analyses will be presented. CONCLUSION The overall prognosis after relapse remains poor. Time to relapse is a significant prognostic factor for postrelapse survival and may help in the design of clinical trials evaluating new agents.

Стилі APA, Harvard, Vancouver, ISO та ін.

Chintagumpala, Murali, Colton Terhune, Lin Tong, Eric Bouffet, Ute Bartels, Michael Fisher, Tim Hassall, et al. "MBCL-26. FACTORS ASSOCIATED WITH LONGER SURVIVAL AFTER FIRST RECURRENCE IN MEDULLOBLASTOMA BY MOLECULAR SUBGROUP AFTER RISK-BASED INITIAL THERAPY." Neuro-Oncology 22, Supplement_3 (December 1, 2020): iii394. http://dx.doi.org/10.1093/neuonc/noaa222.502.

Повний текст джерела

Анотація:

Abstract OBJECTIVE To evaluate differences in time to recurrence among molecular subgroups of medulloblastoma treated on a single protocol and to identify factors associated with survival after first recurrence. METHODS Time to recurrence following SJMB03 treatment was compared across methylation subgroups among relapsed patients. Therapies received subsequent to relapse were noted. Kaplan-Meier methods and log-rank tests were used for statistical analyses. RESULTS 74 of 330 medulloblastoma patients developed recurrence after initial therapy. (38 Standard-Risk; 36 High-Risk). The 2- and 5-year survival after first recurrence was 30.4% and 14.6% respectively. DNA methylation-based subgroups from initial diagnosis were SHH (n=14), Group 3 (n=24), Group 4 (n=26), and unclassified (n=8). None of the pts with WNT MB had recurrent disease. Median time to first recurrence was 1.23, 0.91, and 3.09 years in SHH, Group3, and Group 4 respectively. Group 4 patients had longer post-recurrence survival than others (p-value=0.0169). Clinical risk at diagnosis (p-value=0.337), anaplasia (p-value=0.4032), TP53 (p-value=0.1969), MYC (p-value=0.8967), and MYCN (p value = 0.9404) abnormalities were not associated with post progression survival. Patients who received any therapeutic modality (chemotherapy, re-radiation and second surgery) had longer survival and those who had all three (n=10) had the best outcome (p-value<0.0001). CONCLUSION Outcome after recurrence in medulloblastoma is dismal, however, association with subgroups is still present. Group 4 patients had a longer time to recurrence and post progression survival. No other prognostic factor at initial diagnosis was associated with outcome after recurrence. Patients who received all 3 types of conventional therapy had better survival.

Стилі APA, Harvard, Vancouver, ISO та ін.

Yekedüz, Emre, Ömer Dizdar, Neyran Kertmen, and Sercan Aksoy. "Comparison of Clinical and Pathological Factors Affecting Early and Late Recurrences in Patients with Operable Breast Cancer." Journal of Clinical Medicine 11, no. 9 (April 22, 2022): 2332. http://dx.doi.org/10.3390/jcm11092332.

Повний текст джерела

Анотація:

In this study, we aimed to assess clinicopathological factors affecting early and late recurrences in patients with operable breast cancer. Patients with early (≤5 years) and late (>5 years) recurrences were assessed. Prognostic factors for disease-free survival (DFS) were also evaluated in patients with recurrence. A total of 854 patients were included. There were 432 and 205 patients in the early and late recurrence groups, respectively. In multivariate analyses, HER2+ disease, lymph node metastasis, lymphovascular invasion (LVI), and high tumor grade were associated with increased risk of early recurrence, while HER2+ disease and LVI were associated with decreased risk of late recurrence. In multivariate analyses, presence of HER2+ disease and triple-negative breast cancer (TNBC) were poor prognostic factors for DFS in patients with early recurrence. Presence of LVI and perineural invasion (PNI) were poor prognostic factors for DFS in patients with late recurrence. Molecular subtypes and LVI were effective on the early and late recurrences. However, lymph node positivity and grade were only associated with the early recurrence. After 5 years, LVI and PNI were the prognostic factors for DFS.

Стилі APA, Harvard, Vancouver, ISO та ін.

Agrawal, V., and N. Bharti. "Alterations in Expression of Cell Surface and Cell Cycle Signaling Molecules in Recurrent Nonmuscle Invasive Bladder Cancers: A Tissue Microarray Expression Analysis." Journal of Global Oncology 4, Supplement 2 (October 1, 2018): 94s. http://dx.doi.org/10.1200/jgo.18.60400.

Повний текст джерела

Анотація:

Background: Nonmuscle invasive bladder cancers (NMIBC) are one of the most common urological cancers having a high risk of recurrence and progression. Recurrent tumors may acquire certain molecular alterations responsible for progression of the tumors. Identification of these alterations is important to understand the pathobiology and guide further management. Aim: We studied the differences in expression of cell surface proteins and cell cycle signaling molecules in primary and recurrent NMIBC by immunohistochemistry (IHC) on tissue microarrays (TMA). Methods: Using FFPE tissue, TMA of 82 tumors (40 primary NMIBC and 47 recurrences) were constructed. IHC for growth factor receptors [epidermal growth factor receptor (EGFR), HER2/neu and FGFR3], cell adhesion molecules (E-cadherin and beta-catenin) and cell cycle pathway molecules (p53, p21/WAF1/Cip1 and Ki-67 proliferation index) was performed. A semiquantitative H-score (Histo-score; range 0-300) was calculated according to the intensity (0, negative; 1, weak; 2, moderate; and 3, strong) and percentage of cells stained. < 10% cells showing nuclear p21 expression was considered p21-loss. The differences in expression between the primary and recurrent tumors were analyzed using paired t test. Results: The mean age at presentation was 65.3 ± 13.6 years with a male predominance (n=36). The mean time to recurrence was 33.4 months (range 3-109). Progression in grade and/or stage was seen in 30 (75%) tumors. Time to recurrence was shorter in primary tumors with ≥ 5% Ki-67 proliferation index. There was no significant difference in expression of cell surface proteins between primary and recurrent tumors. Significant p21 loss was seen in recurrent tumors ( P = 0.03) and significantly correlated with loss of surface beta-catenin and nuclear p53 positivity ( P = 0.002). Ki-67 index was higher in recurrent tumors and also correlated with p53 positivity ( P = 0.007). Conclusion: We found no significant differences in expression of cell surface molecules in primary nonmuscle invasive bladder cancers and their recurrences. However, there were significant alterations in expression of molecules of cell cycle signaling pathway and cellular proliferation in recurrent tumors suggesting the role of cell cycle regulators as promising targets in these cancers.

Стилі APA, Harvard, Vancouver, ISO та ін.

Voduc, K. David, Maggie C. U. Cheang, Scott Tyldesley, Karen Gelmon, Torsten O. Nielsen, and Hagen Kennecke. "Breast Cancer Subtypes and the Risk of Local and Regional Relapse." Journal of Clinical Oncology 28, no. 10 (April 1, 2010): 1684–91. http://dx.doi.org/10.1200/jco.2009.24.9284.

Повний текст джерела

Анотація:

Purpose The risk of local and regional relapse associated with each breast cancer molecular subtype was determined in a large cohort of patients with breast cancer. Subtype assignment was accomplished using a validated six-marker immunohistochemical panel applied to tissue microarrays. Patients and Methods Semiquantitative analysis of estrogen receptor (ER), progesterone receptor (PR), Ki-67, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), and cytokeratin (CK) 5/6 was performed on tissue microarrays constructed from 2,985 patients with early invasive breast cancer. Patients were classified into the following categories: luminal A, luminal B, luminal-HER2, HER2 enriched, basal-like, or triple-negative phenotype–nonbasal. Multivariable Cox analysis was used to determine the risk of local or regional relapse associated the intrinsic subtypes, adjusting for standard clinicopathologic factors. Results The intrinsic molecular subtype was successfully determined in 2,985 tumors. The median follow-up time was 12 years, and there have been a total of 325 local recurrences and 227 regional lymph node recurrences. Luminal A tumors (ER or PR positive, HER2 negative, Ki-67 < 1%) had the best prognosis and the lowest rate of local or regional relapse. For patients undergoing breast conservation, HER2-enriched and basal subtypes demonstrated an increased risk of regional recurrence, and this was statistically significant on multivariable analysis. After mastectomy, luminal B, luminal-HER2, HER2-enriched, and basal subtypes were all associated with an increased risk of local and regional relapse on multivariable analysis. Conclusion Luminal A tumors are associated with a low risk of local or regional recurrence. Molecular subtyping of breast tumors using a six-marker immunohistochemical panel can identify patients at increased risk of local and regional recurrence.

Стилі APA, Harvard, Vancouver, ISO та ін.

Kim, Yong Chan, Heun Choi, Young Ah Kim, Yoon Soo Park, Young Hee Seo, Hyukmin Lee, and Kyungwon Lee. "Risk factors and microbiological features of recurrent Escherichia coli bloodstream infections." PLOS ONE 18, no. 1 (January 10, 2023): e0280196. http://dx.doi.org/10.1371/journal.pone.0280196.

Повний текст джерела

Анотація:

Understanding the risk factors and microbiological features in recurrent Escherichia coli BSI is helpful for clinicians. Data of patients with E. coil BSI from 2017 to 2018 were collected. Antimicrobial resistance rates of E. coli were determined. We also identified the ST131 and ESBL genotype to evaluate the molecular epidemiology of E. coli. Whole genome sequencing was conducted on the available ESBL-producing E. coli samples. Of 808 patients with E. coli BSI, 57 (6.31%) experienced recurrence; 29 developed at 4–30 days after initial BSI (early onset recurrence) and 28 at 31–270 days after initial BSI (late onset recurrence). One hundred forty-nine patients with single episode, whose samples were available for determining the molecular epidemiology, were selected for comparison. Vascular catheterization (adjusted odds ratio [aOR], 4.588; 95% confidence interval [CI], 1.049–20.068), ESBL phenotype (aOR, 2.037; 95% CI, 1.037–3.999) and SOFA score ≥9 (aOR, 3.210; 95% CI, 1.359–7.581) were independent risk factors for recurrence. The proportion of ST131 and ESBL genotype was highest in early onset recurrent BSI (41.4% and 41.4%, respectively), from which E. coil had the highest resistance rates to most antimicrobial agents. Whole genome sequencing on 27 of ESBL-producing E. coli (11 from single episode, 11 from early onset recurrence, and 5 from late onset recurrence) demonstrated that various virulence factors, resistant genes, and plasmid types existed in isolates from all types of BSI. Risk factors contributing to the recurrence and microbiological features of E. coli causing recurrent BSI may be helpful for management planning in the clinical setting.

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Molecular factor of recurrence"

Haller, Andrew Clayton. "The roles of the E26 transcription family member, SAM pointed domain-containing ETS transcription factor (SPDEF), in early stage prostate cancer and the development of castration recurrent disease." Thesis, State University of New York at Buffalo, 2013. http://pqdtopen.proquest.com/#viewpdf?dispub=3565756.

Повний текст джерела

Анотація:

One of the greatest problems in prostate cancer management today is accurate identification of patients who require treatment for aggressive disease versus those with indolent disease who are suitable for observational strategies. Histological appearance of the tumor, called Gleason score in the prostate cancer field, is the most predictive measure currently used. However, recent studies in multiple tumor types have shown that histological appearance does not always reflect the underlying molecular phenotype of the lesion. Therefore, in prostate cancer specifically, assessment of a molecular marker of androgen receptor driven epithelial differentiation may have clinical predicative capabilities. SAM pointed domain-containing Ets transcription factor (SPDEF) is a potential AR target gene that has shown to be necessary and sufficient for epithelial cell differentiation in many tissues. Although generally associated with good prognosis, SPDEF's role in cancer in unclear. This study demonstrates, through retrospective immunohistochemical analysis, the utility of SPDEF as a predictive biomarker for patients that have an extended benefit from androgen deprivation therapy (ADT). Furthermore, dual roles of SPDEF to inhibit the initiation and supporting the progression of castrate recurrent disease through novel androgen receptor expression regulation in castrate conditions are shown. In ADT naïve patients, SPDEF did not associate with metastatic disease or an induction of epithelial to mesenchymal transition. However, aggressive tumors tended to be larger, have greater SPDEF variability, and lack vimentin expression; a phenotype that could be explained by a partial EMT. In conclusion, SPDEF may be clinically useful to assess the epithelial phenotype of tumors, and could have utility identifying patients that will respond well to androgen deprivation therapy.

Стилі APA, Harvard, Vancouver, ISO та ін.

RICCITELLI, RICCARDO. "L’utilizzo della Nadroparina Calcica in donne affette da abortività idiopatica ricorrente." Doctoral thesis, Università degli Studi di Roma "Tor Vergata", 2005. http://hdl.handle.net/2108/189.

Повний текст джерела

Анотація:

Inherited and acquired thrombophilias are associated with recurrent pregnancy loss(RPL) and venous thromboembolism(VTE). RPL is a major health problem affecting 1-2% of women at the reproductive age. While chromosomal aberration, endocrinologic dysfunctions and uterine abnormalities are etioloogic factors, a cause of RPL could not be identified. Inherited and acquired thrombophilias can be found in 50-65% of women with RPL of unknown cause, as well as in women with other vascular pathologies such peeclampsia, intrauterine restriction and placental abruption. Gestational outcame in woman with inherited thrombphilias who present with RPL is poor with less than 25% of prengnacies resulting in live birth. The purpose of this study is to verify the safe and efficacy of Nadroparin in RPL.

Стилі APA, Harvard, Vancouver, ISO та ін.

Benzonana, Laura Lina. "Potential effects of anaesthetics on cancer recurrence following surgery : molecular mechanisms." Thesis, Imperial College London, 2012. http://hdl.handle.net/10044/1/39402.

Повний текст джерела

Анотація:

Patients with solid tumours are likely to undergo surgery during the course of their disease. Surgery and anaesthesia may influence the tumour's metastatic potential. Certain anaesthetics are shown to induce cellular phenotypic changes via cellular signalling pathways; including the hypoxia inducible factor (HIF) pathway. HIFs are heavily implicated in tumorigenesis and may play an important role in tumour cell proliferation, migration, invasion and angiogenesis (VEGF signalling). In the current thesis I aimed to investigate the potential impact of isoflurane on tumour cell progression and metastatic potential, as well as the potential anti-cancer effects of helium (a potential insuflation gas) in vitro. In a series of experiments, renal and prostate cancer cells were exposed to different anaesthetics and their effects on the metastatic potential of the cells were observed using different techniques such as western blotting, fluorescent immunocytochemistry, MTT assays, trypan blue assay and migration assays. The data derived from my PhD project show that isoflurane anaesthesia results in an increased metastatic potential of renal cell carcinoma and prostate cancer cells by increasing cell proliferation, migration, and invasion. The mechanism partially responsible for this effect has been shown to be the PI3K/HIF pathway. Furthermore helium was shown to have an anti-cancer effect on both cancer cell lines. These findings may have clinical implications for cancer patient care undergoing surgery under anaesthesia. Understanding the role of anaesthetics on growth and metastasis will defiantly shed light to better treatment options for cancer patients.

Стилі APA, Harvard, Vancouver, ISO та ін.

Makino, Tomokazu. "Carbohydrate antigens as a risk factor for hematogenous recurrence of esophageal squamous cell carcinoma patients." Kyoto University, 2002. http://hdl.handle.net/2433/149342.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

TAKAHASHI, HIROSHI, CHISA HASHIZUME, TAKAHIKO TSUGAWA, YOSHIMASA MORI, and TATSUYA KOBAYASHI. "PROGNOSTIC FACTORS FOR TUMOR RECURRENCE AFTER GAMMA KNIFE RADIOSURGERY OF PARTIALLY RESECTED AND RECURRENT CRANIOPHARYNGIOMAS." Nagoya University School of Medicine, 2012. http://hdl.handle.net/2237/16031.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Sideris, Michail. "The significance of molecular biomarkers in the recurrence of rectal tumors after Transanal Endoscopic Microsurgery." Thesis, King's College London (University of London), 2018. https://kclpure.kcl.ac.uk/portal/en/theses/the-significance-of-molecular-biomarkers-in-the-recurrence-of-rectal-tumors-after-transanal-endoscopic-microsurgery(e16b37d2-b2d4-47fb-9c30-563cd06be58d).html.

Повний текст джерела

Анотація:

Local excision (LE) of rectal cancer has been practiced as a treatment for 30 years on a highly selected group of patients and tumours. A method of local excision which has recently gained wider acceptance in the treatment of low-grade CRC (T1) is transanal endoscopic microsurgery (TEMS). TEMS offers advantages for operative access and oncological clearance compared to those of transanal resection (TAR). A number of studies have shown that TEMS can have almost equal results to radical surgery for early rectal cancer. Radical surgery has the disadvantage of an approximate mortality rate of 5% and a complication rate of around 20%, and it impacts on quality of life due to stomas and of sexual dysfunction. However, TEMS has a higher local recurrence rate, and efforts have been made to classify risk with morphological and histological criteria. Molecular biomarkers in the evaluation of CRC prognosis and treatment stratification have been extensively discussed in the literature. Until now, 3 pathways have been identified to explain the background of CRC molecular pathogenesis. Microsatellite instability (MSI) refers to point mutations in the DNA mismatch repair genes. MSI is currently responsible for 15−20% of CRC cases, and there is enough evidence to support its association with prognosis. Chromosomal instability (CIN) is another pathway of carcinogenesis which affects 85% of CRC cases and has been flagged as a poor prognostic marker. CIN encompasses any structural chromosomal abnormality that results in aneuploidy or polyploidy. The third pathway is related to aberrant hypermethylation of suppressor promoter CpG islands, commonly known as CIMP. v-raf murine sarcoma viral oncogene homolog B (BRAF) encodes a serine-threonine protein kinase that acts as a downstream effector of Kirsten rat sarcoma viral oncogene homolog (KRAS) pathways. Various studies have revealed that v-raf murine sarcoma viral oncogene homolog B V600E (BRAF V600E) mutations appear to be valid prognostic indicators. KRAS is a proto-oncogene that encodes a GTPase, which is involved in facilitating cellular response to extracellular stimuli. KRAS point mutations appear in 40% of CRC cases, and their presence is associated with poor response to anti-epidermal growth factor receptor (anti-EGFR) chemotherapy. However, to date there has been no literature linking biomarkers with stratification of risk for the treatment of rectal cancer following TEMS. Aim: The aim of this dissertation is to assess the significance of these molecular biomarkers in the prediction of local recurrence and prognosis of early rectal cancer following TEMS. Materials and Methods: Initially, we performed a narrative review of the literature to consolidate the evidence available for molecular biomarkers in the evaluation of CRC. We then designed a retrospective pilot study to identify the molecular biomarker status of 41 confirmed CRC cases among 1,446 consecutive referrals for suspected cancer. As part of this study, we retrospectively analysed clinical, biochemical, and histopathological data. Gene profile analysis (KRAS, BRAF) of the specimens was also performed. Following this, we proceeded to analyse data from a series of patients who had undergone TEMS for Stage I rectal cancer at King’s College Hospital (KCH). Demographic, biochemical, histopathological, and follow-up data were prospectively collected. Molecular analysis was prospectively performed in the Advanced Diagnostics Laboratory of KCH to identify the status of BRAF, KRAS, p16 O6-methylguanine-DNA methyltransferase (MGMT), and β-catenin. Finally, we retrospectively collected equivalent data on a 4-year series of 135 confirmed Stage I−IV rectal cancer cases who underwent radical surgery +/- neoadjuvant chemoradiotherapy. Data on the status of the same molecular biomarkers were retrospectively collected. In both cohorts of rectal cancer cases (TEMS/radical surgery +/- additional treatment), the biomarker status was compared with the histopathology and follow-up outcomes, including recurrence and overall cancer-related survival. Results: In our pilot study (41 cases), there was no significant correlation of presenting haemoglobin (Hb) levels with eventual disease staging (p>0.05 for all associations). Patients with right-sided tumours were found to have a lower Hb level than patients with either left-sided or rectal tumours. Hb levels were also significantly lower in patients with the BRAF V600E mutation, although this may be because all 3 patients with the mutation had right-sided tumours. Neither KRAS status nor lymphovascular invasion (LVI) status had a specific correlation with Hb levels. Of 29 specimens of cases who underwent TEMS, there was a statistically significant association between KRAS mutant status and local recurrence (n=6, p=0.037). P16 expression > 5% (mean=10.8%, min=0, max=95) was associated with earlier recurrence within 11.70 months (n=7, p=0.004). Membranous β-catenin expression (n=12, 48%) was also related to KRAS mutant (mt) status (p=0.006) but not to survival (p>0.05). BRAF gene was found to be wild type in all cases tested (n=23). With regard to the specimens of rectal cancer cases who underwent radical excision, 28 cases were Stage I (20.9%), n=30; Stage II (22.4%), n=45; Stage III (33.6%) and n=31 Stage IV (23.1. KRAS mt status was associated with female gender (n=20, p=0.021) and older age (69.62 vs. 62.27, p=0.005). Stage I early cancer subgroup analysis showed that KRAS mt status was associated with distant recurrence of disease (n=4, p=0.045). Conclusions: BRAF V600E mutation seems to be associated with right-sided CRC and iron-deficiency anaemia. This could be used as an adjunct to diagnostic molecular tests for early diagnosis. KRAS, p16, and β-catenin could be used as biomarkers for prediction of local recurrence and stratification of the risk for further surgery in Stage I rectal cancer. Further to this, KRAS may be a predictor of distant recurrence in cases of early stage rectal cancer.

Стилі APA, Harvard, Vancouver, ISO та ін.

Zanardelli, Sara. "ADAMTS13 : molecular recognition of Von Willebrand factor." Thesis, Imperial College London, 2006. http://hdl.handle.net/10044/1/8241.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Fung, Marion R. "Molecular genetics of blood coagulation factor X." Thesis, University of British Columbia, 1988. http://hdl.handle.net/2429/28783.

Повний текст джерела

Анотація:

Thirty thousand colonies of a bovine liver cDNA library were screened with a mixture of synthetic oligodeoxyribonucleotides coding for bovine factor X. Five positive colonies were identified, and plasmid DNA was isolated. Cleavage with restriction endonucleases showed that these plasmids (designated pBXl-5) contained inserts of 1530 bp, 770 bp, 700 bp, 1100 bp and 930 bp. DNA sequence analysis of the plasmid with the largest insert (pBXl) confirmed that bovine factor X cDNAs had been cloned. The cDNA sequence predicts that factor X is synthesized as a single chain precursor in which the light and heavy chains of plasma factor X are linked by the dipeptide Arg-Arg. The cDNA sequence also predicts that factor X is synthesized with a preproleader peptide. It is proposed that at least five specific proteolytic events occur during the conversion of preprofactor X to plasma factor Xa. A human liver cDNA library was screened by colony hybridization with a bovine factor X cDNA probe. Three of the positive plasmids contained overlapping DNA that coded for most of human factor X mRNA. A second human liver cDNA library was screened by in situ hybridization with 32P-labeled human factor X cDNA clones obtained from the first screen. Several clones were isolated that contained longer inserts. DNA sequence analysis of these clones allowed the prediction of the amino acid sequence of the precursor form of human plasma factor X. From these studies, it is predicted that human factor X is synthesized as a single polypeptide chain precursor in which the light and heavy chains of plasma factor X are linked by the tripeptide Arg-Lys-Arg. The cDNA sequence also predicts that human factor X is synthesized as a preproprotein having an aminoterminal leader peptide of 40 amino acid residues. A comparison of the amino acid sequences of human and bovine factor X shows high sequence identity around the calcium- binding regions and catalytic regions but low sequence identity around the nonfunctional regions. A human genomic phage library was screened with a human factor X cDNA as a hybridization probe. Thirty-two overlapping phage clones were isolated. Characterization of six of these clones indicates that over 32 Kbp of contiguous sequence is represented. DNA sequence and restriction map analysis shows that the factor X gene is comprised of at least 8 exons and 7 introns. No clones representing the 5' untranslated region and the prepeptide of the leader sequence were identified. Two further genomic phage libraries and two libraries specific for the 5' region of the factor X gene were screened, but no 5' end clones were obtained. Restriction enzyme mapping and Southern blot analysis indicate that thus far, the human factor X gene maps to 24 Kbp of the human genome. Comparison of the factor X gene with other vitamin K-dependent blood coagulation factor genes reveals homologous exon organization. Within the blood coagulation serine proteases factor X, factor IX, factor VII, and protein C form a closely related gene family.
Medicine, Faculty of
Biochemistry and Molecular Biology, Department of
Graduate

Стилі APA, Harvard, Vancouver, ISO та ін.

Chen, Vivien Mun Yee Medical Sciences Faculty of Medicine UNSW. "The molecular mechanism of tissue factor activation." Awarded by:University of New South Wales. Medical Sciences, 2007. http://handle.unsw.edu.au/1959.4/40556.

Повний текст джерела

Анотація:

Tissue factor (TF) is the essential cofactor for FVIIa. Binding to transmembrane tissue factor increases the catalytic efficiency of FVIIa allowing activation of FX and FIX which initiates coagulation and propagates stable clot. Transmembrane TF resides in a cryptic configuration on the cell surface and in the circulation with low procoagulant activity. However TF can be rapidly switched to an active configuration in order to contribute to thrombus propagation. The precise nature of this switch is unknown, however it is known to be an extracellular event. The extracellular part of TF consists of 2 fibronectin type III domains. The disulfidebond in the membrane proximal domain (Cys186-Cys209) is a cross-strand bond which links adjacent strands in the same ?? sheet. It has the configuration, characteristic dihedral strain energy and bond length of an allosteric disulfide bond. This indicates that it has the potential to undergo thiol/disulfide exchange to change the function of the TF protein. We confirm that the integrity of the Cys186-Cys209 disulfide is required for coagulant function and that tissue factor contains free thiols in the cryptic state which are lost when TF becomes de-encrypted. Membrane based tissue factor procoagulant activity is blocked by the mono-thiol alkylators N-ethylmaleimide and methyl methanethiosulfonate; but increased by ECl/formation of the disulfide via the thiol oxidiser, HgCb or thiol cross-linkers, eimidohexane and bismalemidoethane. The increase in activity correlates with a conformation change in the TF protein adjacent to the disulfide. We show that redox active protein disulfide isomerase is associated with cryptic tissue factor and propose that the cryptic conformation of tissue factor is maintained through formation of an Snitrosylated complex with protein disulfide isomerase. Our results indicate that the activation of TF involves a change of conformation of the domain 2 of TF caused by formation of the cross-strand Cys186-Cys209 disulfide bond. We suggest that this is likely to be the physiological change that facilitates productive binding of FIX and FX in coagulation.

Стилі APA, Harvard, Vancouver, ISO та ін.

Scime, Anthony. "Molecular mechanisms regulating the E2F4 transcription factor." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape7/PQDD_0031/NQ66234.pdf.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Книги з теми "Molecular factor of recurrence"

Antoine, Lafont, and Topol Eric J. 1954-, eds. Arterial remodeling: A critical factor in restenosis. Boston: Kluwer Academic Publishers, 1997.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Akinsanya, A. A. The molecular mechanisms of haemopoietic growth factor action. Manchester: UMIST, 1992.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Colombatti, Alfonso. The superfamily with Von Willebrand factor VA domains. New York: Springer, 1996.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

J, Tymms Martin, ed. Transcription factor protocols. Totowa, N.J: Humana Press, 2000.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

1958-, Skouteris George G., North Atlantic Treaty Organization. Scientific Affairs Division., and NATO Advanced Study Institute on Molecular Aspects of Liver Carcinogenesis (1994 : Delphoi, Greece), eds. Liver carcinogenesis: The molecular pathways. Berlin: Springer-Verlag, 1994.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

International Conference on Tumor Necrosis Factor and Related Cytokines (4th 1992 Veldhoven, Netherlands). Tumor necrosis factor: Molecular and cellular biology and clinical relevance. Edited by Fiers Walter and Buurman Wim A. Basel: Karger, 1993.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

1945-, LeRoith Derek, ed. Insulin-like growth factors: Molecular and cellular aspects. Boca Raton: CRC Press, 1991.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Jr, Roberts Charles T., and Rosenfeld Ron G, eds. The IGF system: Molecular biology, physiology, and clinical applications. Totowa, N.J: Humana Press, 1999.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

N, Goodfellow P., and British Society for Developmental Biology., eds. The Mammalian Y chromosome: Molecular search for the sex-determining factor. Cambridge [England]: Company of Biologists, 1987.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

NATO Advanced Research Workshop on Molecular Mechanisms and Consequences of Activation of Hormone and Growth Factor Receptors (1988 Nauplion, Greece). Activation of hormone and growth factor receptors: Molecular mechanisms and consequences. Dordrecht: Kluwer Academic Publishers, 1990.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Частини книг з теми "Molecular factor of recurrence"

Wojciechowska, Sonia, Zhiqiang Zeng, James A. Lister, Craig J. Ceol, and E. Elizabeth Patton. "Melanoma Regression and Recurrence in Zebrafish." In Methods in Molecular Biology, 143–53. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3771-4_10.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Hill, April, and Rachel McMullen. "Transcription Factor Classes." In Molecular Life Sciences, 1–3. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4614-6436-5_762-1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Hill, April, and Rachel McMullan. "Transcription Factor Classes." In Molecular Life Sciences, 1212–13. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4614-1531-2_762.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Heinrich, Gerhard. "Nerve Growth Factor." In Molecular Cloning of Hormone Genes, 343–63. Totowa, NJ: Humana Press, 1987. http://dx.doi.org/10.1007/978-1-4612-4824-8_14.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Kurepa, Jasmina, and Jan A. Smalle. "Assaying Transcription Factor Stability." In Methods in Molecular Biology, 219–34. Totowa, NJ: Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-154-3_12.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Muszbek, László, Éva Katona, and Adrienne Kerényi. "Assessment of Factor XIII." In Methods in Molecular Biology, 277–93. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7196-1_22.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Mi, Hongmei, Caroline Petitjean, Pierre Vera, and Su Ruan. "Robust Feature Selection to Predict Lung Tumor Recurrence." In Computational Methods for Molecular Imaging, 103–12. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-18431-9_11.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Gartler, Stanley M., R. Scott Hansen, Vinzenz Oji, Heiko Traupe, Julia Horn, Bodo Grimbacher, Srijita Sen-Chowdhry, et al. "Increased Factor IX." In Encyclopedia of Molecular Mechanisms of Disease, 1047. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-29676-8_8394.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Gartler, Stanley M., R. Scott Hansen, Vinzenz Oji, Heiko Traupe, Julia Horn, Bodo Grimbacher, Srijita Sen-Chowdhry, et al. "Increased Factor VIII." In Encyclopedia of Molecular Mechanisms of Disease, 1047. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-29676-8_8396.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Desnick, Robert J., Orlando Guntinas-Lichius, George W. Padberg, Gustav Schonfeld, Xiaobo Lin, Maurizio Averna, Pin Yue, et al. "Factor VIII Deficiency." In Encyclopedia of Molecular Mechanisms of Disease, 631. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-29676-8_8703.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Molecular factor of recurrence"

Cabral, Samira Marcondes, Marcelo Antonini, Raissa Naiara Barros Vasconcelos, Mariana Soares Cardoso, and Matheus de Paula Solino. "IMPACT OF LOCAL RECURRENCE ON PATIENTS WITH BREAST CANCER DIAGNOSIS SUBMITTED TO CONSERVATIVE SURGERY AT HOSPITAL PÚBLICO DO SERVIDOR ESTADUAL." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1060.

Повний текст джерела

Анотація:

Introduction: Breast cancer is a major cause of mortality in Brazil and worldwide. It is a heterogeneous disease with specific molecular subtypes, which are associated with different prognosis and responses to treatment. Objectives: The present study aimed at assessing the incidence of local recurrence in patients undergoing conservative surgery and its impact on overall survival. As a secondary outcome, there are the prognostic factors of local recurrence in addition to the relationship with systemic metastasis. Methods: It is a retrospective cohort including 500 patients submitted to conservative surgical treatment, from March 2014 to March 2019 at Hospital do Servidor Público Estadual de São Paulo. Results: The results are compatible with the literature, with local recurrence in 4% of patients and more relapses with triple-negative subtype; 367 patients had hormonal treatment: five (1.4%) relapsed and 51 patients did not use hormonal treatment, four (7.8%) relapsed. This shows a higher percentage of recurrence in the group without adjuvant hormone therapy when compared to the group that underwent treatment (p=0.016); 7.4% of patients developed metastasis, which was more prevalent in patients diagnosed with triple-negative subtype cancer and pure Her. This group had an estimated probability of survival significantly lower (72.3%) than the group without metastases (98%) (p <0.001). In this cohort, disease-free survival was 93.4% and overall survival was 96% over a median of three years of follow-up. Other prognostic factors, established in the literature, such as age, lymph node involvement, tumor size, in addition to systemic treatment and radiotherapy had no significant difference between patients who did or did not relapse. Conclusion: In this cohort, patients diagnosed with breast cancer and who underwent conservative surgery, evolving with local recurrence, did not present a higher risk of death, and we found tumor biology as a risk factor for locoregional recurrences. Patients who evolved with systemic metastases showed a reduction in the overall survival rate.

Стилі APA, Harvard, Vancouver, ISO та ін.

Kim, E., W. Han, and D. Noh. "Young Age as a Prognostic Factor for Operable Breast Cancer: Significance of Molecular Subtype in Recurrence-Free Survival." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-4063.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Liu, Huan, Yasuyuki Hitoshi, Brenton Paolella, and Mark A. Israel. "Abstract 398: Molecular mechanisms of recurrence of PDGFB-dependent glioma in mice following inhibition of platelet-derived growth factor B expression." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-398.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Chediak, J., J. Eldridge, D. Sobel, B. Maxey, J. Baron, and M. C. Telfer. "FURTHER EVIDENCES OF VON WILLEBRAND FACTOR INVOLVEMENT IN THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644587.

Повний текст джерела

Анотація:

Laboratory findings of TTP include severe thrombocytopenia and marked anemia due to intravascular hemolysis. The pathogenesis of the thrombocytopenia is poorly understood. Possible mechanisms include the presence of a platelet aggregating factor (JCI 76:1330, 1935), a calcium dependent protease (Blood 63:310a, 1986), abnormal prostaglandin production or metabolism, and an excessive consumption of high molecular weight forms of von Uillebrand factor (VUF). Von Willebrand factor proteins from 12 patients (pts) diagnosed as having TTP were studied. They include 8 females and 4 males; nine were studied during the acute presentation and seven pts also during the remission period. Three pts died during the acute event. None of the pts had a recurrence. Control subjects include both normal individuals and thrombocytopenic pts due to a variety of underlying diseases including marrow aplasia and immune thrombocytopenia, but excluding pts with DIC or suffering infection. Plasmas were tested for VWF antigen and Ristocetin Cofactor (RiCof) activity. The electrophoretic mobility (CIE) of VWF:Ag was also assessed and the ratio VWF:RiCof to VWF:Ag was determined. Statistical analysis including p values will be reported. Results:These results suggest that during the acute event there is an excessive consumption of large VWF multimers and the ratio VWF:RiCof/VWF:Ag could be used to corroborate the diagnosis of TTP and by doing sequential measurements to monitor the response to therapy.

Стилі APA, Harvard, Vancouver, ISO та ін.

Eggersmann, TK, A. Seiler, R. Würstlein, J. Kumbrink, D. Mayr, S. Mahner, and N. Harbeck. "Long-term distant recurrence in premenopausal receptor-positive early stage breast cancer: Prognostic impact of molecular subtypes, risk of recurrence score, and clinical-pathological factors." In 62. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe – DGGG'18. Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1671515.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Jara-Palomares, Luis, Samira Marin-Romero, Maria Isabel Asensio-Cruz, Teresa Elias-Hernandez, Rocio Ortega-Rivera, Remedios Otero-Candelera, Emilio Montero-Romero, et al. "Anti-Factor Xa levels correlate with recurrent venous thromboembolism and clinically relevant bleeding in patients receiving low-molecular-weight heparin." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa1460.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Vidal, David Barbosa Duarte, Francisca Janice Lopes Sales, Iandra Freire de Oliveira, and Roberto César Pereira Lima-Júnior. "HMGB1 EXPRESSION IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER: IS A GOOD MARKER FOR PROGNOSIS?" In XXIV Congresso Brasileiro de Mastologia. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s1042.

Повний текст джерела

Анотація:

Introduction: Breast cancer is one of the most frequent neoplasms worldwide, contributing to women’s morbimortality. Triple-negative breast cancer (TNBC) is a highly aggressive subtype of cancer marked by negative estrogen receptors, progesterone receptors, and lack of the human epidermal growth factor 2 (C-erbB2, HER2/neu) gene overexpression. The high mobility group box-1 (HMGB1) is considered a DAMP (Molecular Pattern Associated Damage) regulating malignant tumorigenesis, proliferation, and metastasis. Objective: The HMGB1 expression was investigated as a prognostic factor for the TNBC. Methods: Clinicopathological data were assessed from 85 patients treated at the Haroldo Juaçaba Hospital (Ethics Committee approval number 18946313.3.0000.5528). Besides, a tissue microarray (TMA) block was constructed containing the patient. Then, immunofluorescence for HMGB1 was performed to quantify the intensity of expression and the percentage of fluorescent cells with cytoplasmic HMGB1 (cHMGB1) expression. Immunohistochemistry was performed for HMGB1. The analysis statistic is considered as significant with a statistical value of p <0.05. Results: The clinicopathological data analysis indicated that patients were older than 50 years (68.2%) and diagnosed with grade 2–3 ductal carcinomas (91.8%). Tumor metastasis was observed in 9.9% of cases. In all, 66.7% of TNBC patients who had adjuvant chemotherapy was low expression of HMGB1 (p <0.05). In addition, tumor cells that presented low cHMGB1 fluorescence demonstrated an increased local tumor recurrence compared with high expressing tumors (p<0.05). A 5 year overall survival was similar between patients with low versus high cHMGB1 expression (p=0.155).

Стилі APA, Harvard, Vancouver, ISO та ін.

Yoshimura, Adriana Akemi, André Mattar, Bruna S. Mota, Carlos Elias Fristachi, Eduardo Carvalho Pessoa, Felipe Eduardo Andrade, Giuliano Tosello, et al. "A MULTICENTRIC STUDY ON BREAST CANCER IN ULTRA YOUNG WOMEN: II – HISTOPATHOLOGIC AND MOLECULAR DATA." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1062.

Повний текст джерела

Анотація:

Introduction: Ultra young women (UYW) is defined as women aged up to 30 years. UYW with BC share some unfavorable biological tumor characteristics as larger size at diagnosis, higher loca-regional recurrence rate and lower survival, and have been merited specialized care. Objectives: We aimed to determine histopathological and molecular characteristics of BC in UYW. Methods: We carried out a multicentric, observational, retrospective study of consecutive UYW patients with BC. Only patients with infiltrating BC were included. Nine Mastology Centers located in the State of São Paulo took part in the research. The follow data were recorded: pathological tumor histology, number of positive lymph nodes multicentricity/multifocality, presence or absence of peritumoral vascular invasion (PVI), histologic grade (HG), pT category, estrogen receptor (ER), progesterone receptor (PR), HER2 and Ki67. We classified the neoplasias into five molecular subtypes by immunohistochemistry, based on modified recommendations of St. Gallen Consensus (2013): Luminal A-like, Luminal B-like HER2-, Luminal B-like HER2+, HER2 overexpressed (HER2+) non luminal and Triple-Negative. The frequency of the analysed parameters were calculated. The research protocol was approved by the Ethics Committee of all Collaborative Centers. Individual informed consent was waived. Results: Invasive carcinoma of no special type (NST) was observed in 243 patients (88%), and infiltrative lobular tumor was extremely rare, being found in 1.1%. The tumor size in surgical specimens was above 20 mm in 54% (in 10% there was no more evidence of tumor after neoadjuvant treatment). We found 52.6% of patients without invasion in lymph nodes (LN) whereas in 22.2% there was more than four LNs involved. Multifocality was seen in 12.4%. HG was 2 or 3 in 98.3%. In 67.5% the tumors expressed ER, 59.4% gR, and 25.1% were HER2+. In 61.5% Ki67 was higher than 20%. Tumor molecular subtypes were classified in 16.6% Luminal A-like, 35.9% Luminal B-like HER2-, 15.1% Luminal B-like HER2+, 9.3% HER2+ non-luminal and in 22.9% Basal-like. Conclusions: Our data from UYW with BC revealed unfavorable characteristics, with frequent adverse pathological and molecular prognostic factors.

Стилі APA, Harvard, Vancouver, ISO та ін.

Belluco, Rosana Zabulon Feijó, Melissa de Andrade Baqueiro, Flávio Lúcio Vasconcelos, Paulo Eduardo Silva Belluco, and Carmelia Matos Santiago Reis. "MOLECULAR SUBTYPES OF BREAST CANCER IN WOMEN SEEN AT A PUBLIC HOSPITAL IN THE FEDERAL DISTRICT." In XXIV Congresso Brasileiro de Mastologia. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s1057.

Повний текст джерела

Анотація:

Introduction: Breast cancer is the most common neoplasm among women worldwide. The advent of genetic studies and DNA microarrays and their proteins had made it possible to correlate the patterns of gene expression of each type of cancer in different women, associate them with other prognostic factors, and verify the clinical evolution and therapeutic response. The immunohistochemistry (IHC) technique is based on the detection of protein cellular constituents — antigens — and based on the identification and classification of specific cells in the tissue sample. Immunohistochemical panels have been traced to determine breast cancer subtypes, to reproduce gene expression profiles, which have specific treatments. Different molecular subtypes have been established associated with differences in survival and treatment. The four main types in clinical practice are luminal A, luminal B, HER2 overexpression, and triple negative. Objective: The aim of this study was to trace the epidemiological profile of the molecular subtypes of breast cancer in women treated at the Hospital Regional da Asa Norte-Brasília, DF. Methods: Cross-sectional, longitudinal, and retrospective study through the analysis of 138 electronic medical records stored on the TrakCare® platform of cases of women diagnosed with breast cancer, with known histological type, and who underwent IHC examination to determine the molecular subtype. The study included women who attended between January 2015 and December 2020, in the Mastology Department of Hospital Regional da Asa Norte (HRAN). Results: The most common molecular subtype was luminal B, with 65 of the total cases, equivalent to 47.1%. Luminal A subtype was the subtype of 41 cases, equivalent to 29% and being the second most observed subtype. Triple negative was recorded in 21 of the cases, corresponding to 15.2%. The least observed subtype was HER2 overexpression, with 11 cases and 7.9% of the cases. Two participants had local recurrence within less than 2 years of diagnosis, changing from luminal A to luminal B, and luminal B to luminal A. The mean age of the women in the study at the time of diagnosis of breast cancer was 51.5 years, with age extremes of 17 and 86 years. Conclusion: The most prevalent molecular subtype in this sample studied was luminal B, corroborating other studies carried out in the Brazilian population and diverging from the international literature, in which it is the luminal A subtype. Epidemiological knowledge can guide the elaboration of public policies to improve the quality of care, such as drug planning and neoadjuvant and adjuvant treatments with the best results.

Стилі APA, Harvard, Vancouver, ISO та ін.

Lara, Édipo Giovani França, Selene Elifio Esposito, and José Claudio Casali da Rocha. "IMPACT OF PHYSICAL ACTIVITY ON PHYSICAL FITNESS AND BODY COMPOSITION OF WOMEN AFTER BREAST CANCER TREATMENT." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2013.

Повний текст джерела

Анотація:

Introduction: Much has been discussed about benefits of physical exercise in women who have ended breast cancer treatment, which includes not only the improvement of their quality of life but also a remarkable decreased risk of recurrence. To achieve these benefits, it is important that the parameters for prescribing and monitoring physical activity for this population are well defined, as well as the evaluation of factors that may interfere with the results and the adherence to physical exercises. Objectives: To assess the impact of physical exercise on physical fitness and body composition in women who have ended breast cancer curative treatment and to evaluate the impact of physical exercise on women with binge eating disorder. Methods: This prospective study included 107 women between 18 and 60 years of age shortly after the end of their curative treatment for breast cancer (surgery and/or chemotherapy and/or radiotherapy). The participants, after signing the informed consent form, were motivated to do aerobic exercises, localized muscular strength/resistance, and flexibility exercises. Intervention consisted of sets of physical exercises prescribed to all participants by a physical educator in progressive intensities and volumes over the months, according to their adaptive responses, considering individual capabilities and limitations. All participants were evaluated at entrance for cardiovascular morbidities and oriented how to exercise by their own at their homes. Evaluations including body composition, VO2max, and localized muscle resistance were performed at pre-intervention (basal), after 6 and 9 months of intervention. Results: A total of 78 (72.8%) women adhered to the training program, and 29 (27.2%) chose not to adhere. After 9 months of regular and individualized intervention, adherent women showed significantly better results in all variables of body composition and physical fitness: body mass (-4.38±3.67 kg; p0.05), as well as it was not influenced by breast cancer characteristics (e.g., histology, stage, and molecular subtypes) or treatment (i.e., mastectomy, axillary surgery, chemotherapy, or radiotherapy; p>0.05). Conclusion: Our study shows that individualized programs of self-training sets of physical exercises, remotely guided by a physical education professional, could improve the body composition and physical fitness of women in surveillance after breast cancer, regardless of the history of breast cancer or treatment, showing that it is possible to reduce risk factors associated with breast cancer recurrence and to contribute to a better quality of life for these women.

Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Molecular factor of recurrence"

Chaosu, E. Molecular Analysis of the Cripto Growth Factor Receptor. Fort Belvoir, VA: Defense Technical Information Center, May 1999. http://dx.doi.org/10.21236/ada381313.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Yang, Zeng-Quan, and Kezhong Zhang. Endoplasmic Reticulum-Associated Degradation Factor ERLIN2: Oncogenic Roles and Molecular Targeting of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, June 2012. http://dx.doi.org/10.21236/ada613824.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Zhang, Kezhong. Endoplasmic Reticulum-Associated Degradation Factor ERLIN2: Oncogenic Roles and Molecular Targeting of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, June 2012. http://dx.doi.org/10.21236/ada603934.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ragunathan, Yoithapprabhunath Thuckanaickenpalayam, Srichinthu Kenniyan Kumar, Deepak Gupta, Diksha Singh, Swetha Pasupuleti, and Madhavan Nirmal Ramdas. Effectiveness of Neoadjuvant Molecular-Targeted Chemotherapy in Ameloblastoma - A Systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0018.

Повний текст джерела

Анотація:

Review question / Objective: The aim of this article is to obtain an in-depth review of ameloblastoma tumor to determine the available level of evidence and the possible benefit of targeted therapeutics for the treatment of BRAF V600E mutation in ameloblastoma tumor. Condition being studied: Ameloblastoma is an epithelium-derived odontogenic tumour that evolved since the prehistoric era. Ameloblastoma is unique among the odontogenic neoplasms occurring in the jaws, because of its locally invasive behaviour and high recurrence rate. Facial asymmetry, displacement of teeth, malocclusion, and pathologic fractures are some of the asymmetrical features that ameloblastoma is known to cause. If left untreated, they often lead to wide tissue destruction and deformity. For the treatment of ameloblastomas, conventional chemotherapy and radiation have been unexplored or contraindicated and to date, wide surgical resection is the only treatment of choice for ameloblastoma tumours, resulting in post-treatment compromised quality of life in the individuals.

Стилі APA, Harvard, Vancouver, ISO та ін.

Johnson, Christine C. Molecular Epidemiology of Breast Cancer: Establishment of an at Risk Cohort and Methods to Improve the Collection and Use of Risk Factor Data. Fort Belvoir, VA: Defense Technical Information Center, October 2000. http://dx.doi.org/10.21236/ada395039.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Paran, Ilan, and Molly Jahn. Analysis of Quantitative Traits in Pepper Using Molecular Markers. United States Department of Agriculture, January 2000. http://dx.doi.org/10.32747/2000.7570562.bard.

Повний текст джерела

Анотація:

Original objectives: The overall goal of the proposal was to determine the genetic and molecular control of pathways leading to the production of secondary metabolites determining major fruit quality traits in pepper. The specific objectives were to: (1) Generate a molecular map of pepper based on simple sequence repeat (SSR) markers. (2) Map QTL for capsaicinoids content (3) Determine possible association between capsaicinoids and carotenoid content and structural genes for capsaicinoid and carotenoid biosynthesis. (4) Map QTL for quantitative traits controlling additional fruit traits. (5) Map fruit-specific ESTs and determine possible association with fruit QTL (6) Map the C locus that determines the presence and absence of capsaicinoids in pepper fruit and identify candidate genes for C. Background: Pungency, color, fruit shape and fruit size are among the most important fruit quality characteristics of pepper. Despite the importance of the pepper crop both in the USA and Israel, the genetic basis of these traits was only little known prior to the studies conducted in the present proposal. In addition, molecular tools for use in pepper improvement were lacking. Major conclusions and achievements: Our studies enabled the development of a saturated genetic map of pepper that includes numerous simple sequence repeat (SSR) markers and the integration of several independent maps into a single resource map that consists of over 2000 markers. Unlike previous maps that consisted mostly of tomato-originated RFLP markers, the SSR-based map consists of largely pepper markers. Therefore, the SSR and integrated maps provide ample of tools for use in marker-assisted selection for diverse targets throughout the Capsicum genome. We determined the genetic and molecular bases of qualitative and quantitative variation of pungency, the most unique characteristics of pepper fruit. We mapped and subsequently cloned the Pun1 gene that serves as a master key for capsaicinoids accumulation and showed that it is an acyltransferase. By sequencing the Pun1 gene in pungent and non-pungent cultivars we identified a deletion that abolishes the expression of the gene in the latter cultivars. We also identified QTLs that control capsaicinoids content and therefore pungency level. These genes will allow pepper breeders to manipulate the level of pungency for specific agricultural and industrial purposes. In addition to pungency we identified genes and QTLs that control other key developmental processes of fruit development such as color, texture and fruit shape. The A gene controlling anthocyanin accumulation in the immature fruit was found as the ortholog of the petunia transcription factor Anthocyanin2. The S gene required for the soft flesh and deciduous fruit nature typical of wild peppers was identified as the ortholog of tomato polygalacturonase. We identified two major QTLs controlling fruit shape, fs3.1 and fs10.1, that differentiate between elongated and blocky and round fruit shapes, respectively. Scientific and agricultural implications: Our studies allowed significant advancement of our understanding at the genetic and molecular levels of important processes of pepper fruit development. Concomitantly to gaining biological knowledge, we were able to develop molecular tools that can be implemented for pepper improvement.

Стилі APA, Harvard, Vancouver, ISO та ін.

O'Neill, Sharman, Abraham Halevy, and Amihud Borochov. Molecular Genetic Analysis of Pollination-Induced Senescence in Phalaenopsis Orchids. United States Department of Agriculture, 1991. http://dx.doi.org/10.32747/1991.7612837.bard.

Повний текст джерела

Анотація:

The project investigated the molecular genetic and biochemical basis of pollination-induced senescence of Phalaenopsis flowers. This experimental system offered unique advantages in that senescence is strictly regulated by pollination, providing the basis to experimentally initiate and synchronize senescence in populations of flowers. The postpollination syndrome in the Phalaenopsis orchid system was dissected by investigating the temporal and spatial regulation of ACC synthase gene expression. In the stigma, pollen-borne auxin induces the expression of the auxin-regulated ACC synthase (PS-ACS2) gene, resulting in ACC synthesis within 1 h following pollination. Newly formed ACC is oxidized by basal constitutive ACC oxidase to ethylene, which then induces the expression of the ethylene-regulated ACC synthase(PS-ACS1) and oxidase (ACO1) genes for further autocatalytic production of ethylene. It is speculated that during the 6-h period following pollination, emasculation leads to the production or release of a sensitivity factor that sensitizes the cells of the stigma to ethylene. ACC and ethylene molecules are translocated from the stigma to the labellum and perianth where ethylene induces the expression of PS-ACS1 and ACO1 resulting in an increased production of ACC and ethylene. Organ-localized ethylene is responsible for inrolling and senescence of the labellum and perianth. The regulation of ethylene sensitivity and signal transduction events in pollinated flowers was also investigated. The increase in ethylene sensitivity appeared in both the flower column and the perianth, and was detected as early as 4 h after pollination. The increase in ethylene sensitivity following pollination was not dependent on endogenous ethylene production. Application of linoleic and linoleic acids to Phalaenopsis and Dendrobium flowers enhanced their senescence and promoted ethylene production. Several major lipoxygenase pathway products including JA-ME, traumatic acid, trans-2-hexenal and cis-3-hexenol, also enhanced flower senescence. However, lipoxygenase appears to not be directly involved in the endogenous regulation of pollination-induced Phalaenopsis and Dendrobium flower senescence. The data suggest that short-chain saturated fatty acids may be the ethylene "sensitivity factors" produced following pollination, and that their mode of action involves a decrease in the order of specific regions i the membrane lipid bilayer, consequently altering ethylene action. Examination of potential signal transduction intermediates indicate a direct involvement of GTP-binding proteins, calcium ions and protein phosphorylation in the cellular signal transduction response to ethylene following pollination. Modulations of cytosolic calcium levels allowed us to modify the flowers responsiveness to ethylene.

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!